Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G–seropositive neuromyelitis optica spectrum disorder: a case series report
In this retrospective case series, satralizumab was effective and well tolerated in patients with NMOSD who switched from eculizumab due to route of administration/patient preference or inadequate disease control. These outcomes align with the long-term efficacy and safety outcomes with satralizumab in the phase 3 SAkura clinical trials.
Authors
- Ahmed Z. Obeidat (ORCID: https://orcid.org/0000-0002-3549-3277)
- Lisa Ferayorni
- Adnan Subei
- Hesham Abboud (ORCID: https://orcid.org/0000-0001-5346-8254)
- Rosemarie Walch
- Robert K. Shin (ORCID: https://orcid.org/0000-0002-1313-8071)
- Buse Sengul
- Paige Goulette
- Shervin Gholizadeh (ORCID: https://orcid.org/0000-0002-5321-5393)
- Robert Pace
- Jeanie Coté
Institutions
- Medical College of Wisconsin (US)
- University Hospitals of Cleveland (US)
- Memorial Healthcare System (US)
- Texas Neurology (US)
- University of Virginia (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1526563
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.36
Funders
- Genentech